ABT-263isaBH3mimeticthatinhibitsBcl-2,Bcl-ω,andBcl-xl.ABT-263’sinhibitionofBcl-xlresultsinthrombocytopeniabyinducingapoptoticdeathofplatelets,limitingitsusage.ABT-263exhibitsanticancerchemotherapeuticactivityandshowssomebenefitinclinicaltrials.Inchroniclymphocyticleukemia(CLL)cells,ABT-263inhibitscellproliferation.Incellularandanimalmodelsofcancerswithsolidtumors,ABT-263enhancesthechemotherapeuticactivityofseveralco-admiNISTeredtreatments.
| CasNo. | 923564-51-6 |
|---|---|
| Purity | ≥98% |
| Formula | C47H55ClF3N5O6S3 |
| FormulaWt. | 974.61 |
| IUPACName | 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide |
| Synonym | Navitoclax,A-855071 |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | 4°C |
|---|---|
| ShipTemp | Ambient |
| MSDS | A0777MSDSPDF |
|---|---|
| InfoSheet | A0777InfoSheetPDF |
DebrincatMA,PleinesI,LeboisM,etal.BCL-2isdispensableforthrombopoiesisandplateletsurvival.CellDeathDis.2015Apr16;6:e1721.PMID:25880088.
KhawSL,MérinoD,AndersonMA,etal.BothleukaemicandnormalperipheralBlymphoidcellsarehighlysensitivetotheselectivepharmacologicalinhibitionofprosurvivalBcl-2withABT-199.Leukemia.2014Jan9.[Epubaheadofprint].PMID:24402163.
BalakrishnanK,GandhiV.Bcl-2antagonists:aproofofconceptforCLLtherapy.InvestNewDrugs.2013Oct;31(5):1384-94.PMID:23907405.
RudinCM,HannCL,GaronEB,etal.PhaseIIstudyofsingle-agentnavitoclax(ABT-263)andbioMarkercorrelatesinpatientswithrelapsedsmallcelllungcancer.ClinCancerRes.2012Jun1;18(11):3163-9.PMID:22496272.
ChenJ,JinS,AbrahamV,etal.TheBcl-2/Bcl-X(L)/Bcl-winhibitor,navitoclax,enhancestheactivityofchemotherapeuticagentsinvitroandinvivo.MolCancerTher.2011Dec;10(12):2340-9.PMID:21914853.
